Statistics for Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
Total visits
| views | |
|---|---|
| Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study | 2 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:289efa2b-f4e2-483f-8ff3-fddd7b4e3330 | 23 |
| java.util.UUID:8fbe0d7c-a6de-4ccc-ad5f-e3739df87e46 | 10 |
| java.util.UUID:f5c0fe0f-132f-4994-9fae-26116497e15e | 6 |
| Lonial2021LongerTerm-CCBYNC.pdf | 5 |
Top country views
| views | |
|---|---|
| United States | 2 |
Top city views
| views | |
|---|---|
| Indianapolis | 2 |